Decembre 17, 2025 — CDG Invest Growth announces the exit of Capmezzanine III Fund from Soludia Maghreb, a key player in the manufacturing of hemodialysis products in Morocco. This transaction consists in Sothema’s strategic acquisition of 99.99% of Soludia Maghreb’s share capital and voting rights.
Founded in 1998, Soludia Maghreb is a pharmaceutical company specializing in the manufacturing of hemodialysis concentrates and the distribution of pharmaceutical products and medical devices sourced from international laboratories.
CDG Invest Growth joined Soludia Maghreb’s shareholding structure in December 2021 and supported the company in the execution of its development projects, including the upgrade of its industrial platform, the diversification of its product offering into new products and therapeutic areas, the strengthening of its sales force, its geographic expansion, and its development through external growth.
This transaction marks the successful completion of a close partnership with Soludia Maghreb during key phases of its development and results in a smooth transition to Sothema Group, opening a new phase of growth for the company.
Hassan Laaziri, CEO of CDG Invest Growth, stated:
“This transaction reflects the successful partnership between CDG Invest Growth and Soludia Maghreb, built on the strengthening of the company’s operational fundamentals and the acceleration of its growth trajectory. The handover to a leading industrial player such as Sothema represents a major milestone and opens up enhanced industrial and commercial development prospects for Soludia Maghreb.”
CDG Invest Growth was advised in this transaction by DLA Piper (legal counsel)
